Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Vertex ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Truist Financial from $460.00 to $520.00 in a research report issued on Tuesday,Benzinga ...

VRTX stock has fared well in recent years ... amid label expansion and better price realization. Notably, 93% of the company’s total sales are generated by Trikafta/Kaftrio.

VRTX stock has fared well in recent years ... the treatment of cystic fibrosis – amid label expansion and better price realization. Notably, 93% of the company’s total sales are generated ...

Gas prices dropped again ... CIEN, GIS, MDLZ, CRWD, MRK, NOW, VRTX, HPE May Stock Recovery as Economy Sends Mixed Signals The Portfolio Selector features the Argus Focus List, a group of 30 ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

The firm is raising its price target on the stock to reflect updated sales expectations ... firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.